Volume 25, Issue 4 (In Press_ Winter 2021 2021)                   2021, 25(4): 4-4 | Back to browse issues page

XML Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Haji Sobhani S, Daei M M, Dodangeh S, Hajikarimi M, Mohammadi N. Impact of metabolic syndrome in patients with acute myocardial after thrombolytic therapy. Journal of Inflammatory Diseases. 2021; 25 (4) :4-4
URL: http://journal.qums.ac.ir/article-1-3247-en.html
1- Clinical Research Development Unit, Bou Ali Sina Hospital, Qazvin University of Medical Sciences, Qazvin, Iran.
2- Clinical Research Development Unit, Bou Ali Sina Hospital, Qazvin University of Medical Sciences, Qazvin, Iran
3- Children Growth Research Center, Research Institute for Prevention of Non-Communicable Diseases, Qazvin University of Medical Sciences, Qazvin, Iran
4- Clinical Research Development Unit, Bou Ali Sina Hospital, Qazvin University of Medical Sciences, Qazvin, Iran. , majidhajikarimi57@gmail.com
5- Department of Social Medicine, Qazvin University of Medical Sciences, Qazvin, Iran
Abstract:   (116 Views)
Background: The metabolic syndrome (MetS) is a group of conditions that happen together and increase risk of heart disorders. MetS will be detected base on physical examination and blood tests. It has known diagnostic characteristic criteria. This syndrome is extremely prevalent in patients with acute myocardial infarction. This study aimed to determine the prevalence of MetS and the relationship between MetS and response to treatment in patients suffering from acute myocardial infarction under fibrinolytic treatment.
Methods: In this cross-sectional study, 145 patients with acute ST-elevation myocardial infarction (STEMI) were enrolled and were candidates for thrombolytic therapy referring  to Bou Ali Sina hospital in Qazvin, Iran, between January 2018 and January 2019. Then, the patients were divided into two groups with and without metabolic syndrome according to NCEP ATP III definition. In each group, the present of ST resolution more than 50% in electrocardiogram (ECG) was evaluated 90 minutes after thrombolytic administration. In addition, angiographic information and Left ventricular ejection fraction (LVEF) were compared in the two groups.
Results: Overall prevalence of MetS was 57.2% in the study population. After treatment, ST segment resolution more than 50% in ECG, the number of involved coronary vessels, the Thrombolysis in Myocardial Infarction (TIMI) flow grade, mean LVEF, type of myocardial infarction (MI) were similar in both groups (with and without MetS).
Conclusion: Our study indicates that MetS does not affect the response rate to thrombolytic treatment.
     
Type of Study: Research | Subject: Cardiology

Add your comments about this article : Your username or Email:
CAPTCHA

Send email to the article author


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2022 CC BY-NC 4.0 | Journal of Inflammatory Diseases

Designed & Developed by : Yektaweb